home All News open_in_new Full Article

ProteinQure Announces First Patient Dosed in Phase I Clinical Trial of PQ203 in Advanced Metastatic Cancer

TORONTO — ProteinQure, a Toronto-based biotech company pioneering computational peptide drug discovery, today announced the successful dosing of the first patient in its Phase I clinical trial evaluating PQ203 – a novel, rationally designed peptide therapeutic for advanced metastatic solid tumors. “Dosing our first patient with PQ203 represents a defining moment not just for ProteinQure, […]


today 2 w. ago attach_file Science

attach_file Other
attach_file Politics
attach_file Other
attach_file Science
attach_file Other
attach_file Other
attach_file Events
attach_file Economics
attach_file Other
attach_file Other
attach_file Other
attach_file Politics
attach_file Economics
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Economics
attach_file Culture


ID: 2466567694
Add Watch Country

arrow_drop_down